Syros Pharmaceuticals (Syros Pharmaceuticals) Margin of Safety % (DCF FCF Based) : N/A (As of Apr. 29, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Syros Pharmaceuticals Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Syros Pharmaceuticals's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Syros Pharmaceuticals's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Syros Pharmaceuticals's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syros Pharmaceuticals's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syros Pharmaceuticals's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Syros Pharmaceuticals's Margin of Safety % (DCF FCF Based) falls into.

Syros Pharmaceuticals Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Syros Pharmaceuticals's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Syros Pharmaceuticals (Syros Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syros Pharmaceuticals Inc (NAS:SYRS) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

0S90:Germany 0S90:Germany

Address

35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140

Website

https://www.syros.com

Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. It is mainly involved in the segments of pharmaceutical, biotechnology, and other related markets that address gene control and cancer. The Company operates only in the United States.

Executives

Srinivas Akkaraju	director	565 EVERETT AVENUE, PALO ALTO CA 94301
David Roth	officer: Chief Medical Officer	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Eric R Olson	officer: Chief Scientific Officer	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, SUITE 300, CAMBRIDGE MA 02139
Timothy Tyson	director	ONE ENTERPRISE, ALISO VIEJO CA 92656
Andrew M. Oh	director	C/O RUBIUS THERAPEUTICS, 325 VASSAR ST., STE. 1A, CAMBRIDGE MA 02139
Jason Haas	officer: Chief Financial Officer	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Chee Conley	officer: Chief Commercial Officer	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Deborah Dunsire	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Kristin Stephens	officer: Chief Development Officer	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Richard A Young	director	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Sue Gail Eckhardt	director	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Mark J Alles	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jeremy P. Springhorn	officer: Chief Business Officer	C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421
Arch Venture Fund Vii, L.p.	10 percent owner	8755 W HIGGINS, SUITE 1025, Chicago IL 60631
Alice Tsang Shaw	director	MASSACHUSETTS GENERAL HOSPITAL, 55 FRUIT ST., #148, BOSTON MA 02114